Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
This study has been completed.
Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00140049
  Purpose

To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.


Condition Intervention Phase
Glaucoma, Open Angle
Ocular Hypertension
 Drug: Xalacom
Drug: Cosopt
 Phase IV

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma High Blood Pressure
Drug Information available for: Latanoprost Dorzolamide Dorzolamide hydrochloride Timolol Timolol maleate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The mean IOP measurements obtained in the study eye at each time point

Estimated Enrollment: 238
Study Start Date: July 2005
Study Completion Date: July 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening

Exclusion Criteria:

  • Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.
  • History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00140049

Locations
France
Pfizer Investigational Site
Lyon, France, 69437
Pfizer Investigational Site
Clermont-ferrand, France, 63003
Pfizer Investigational Site
Marseille Cedex 05, France, 13385
Pfizer Investigational Site
SAINT HERBLAIN, France, 44800
Pfizer Investigational Site
Caen, France, 14033
Germany
Pfizer Investigational Site
Starnberg, Germany, 82319
Pfizer Investigational Site
Regenstauf, Germany, 93128
Pfizer Investigational Site
Schorndorf, Germany, 73614
Pfizer Investigational Site
Darmstadt, Germany, 64297
Pfizer Investigational Site
Landau / Pfalz, Germany, 76829
Pfizer Investigational Site
Darmstadt, Germany, 64283
Greece
Pfizer Investigational Site
Alexandroupoli, Greece, 68100
Pfizer Investigational Site
Larisa, Greece, 41110
Greece, Crete
Pfizer Investigational Site
Heraklion, Crete, Greece, 71110
Greece, Macedonia
Pfizer Investigational Site
Thessaloniki, Macedonia, Greece, 546 36
Italy
Pfizer Investigational Site
Chieti, Italy, 66013
Pfizer Investigational Site
Genova, Italy, 16132
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Pisa, Italy, 56126
Pfizer Investigational Site
Monza (MI), Italy, 20052
Pfizer Investigational Site
Foggia, Italy, 71100
Sweden
Pfizer Investigational Site
Molndal, Sweden, 431 80
Pfizer Investigational Site
Malmo, Sweden, 205 02
Pfizer Investigational Site
örebro, Sweden, 703 61
Pfizer Investigational Site
Sundsvall, Sweden, 851 86
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Study ID Numbers: A6641038
Study First Received: August 29, 2005
Last Updated: November 29, 2007
ClinicalTrials.gov Identifier: NCT00140049  
Health Authority: France: Ministry of Health

Study placed in the following topic categories:
Glaucoma
Eye Diseases
Glaucoma, Open-Angle
Vascular Diseases
Timolol
 Latanoprost
Dorzolamide
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 13, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services